-+ 0.00%
-+ 0.00%
-+ 0.00%

OS Therapies Begins UK Conditional Approval Application for Herlystic

PUBT·11/10/2026 13:17:25
Listen to the news
OS Therapies Begins UK Conditional Approval Application for Herlystic
  • OS Therapies initiated a UK conditional marketing authorization application for Herlystic to prevent or delay recurrence in fully resected pulmonary metastatic osteosarcoma.
  • Submission acceptance is expected in the fourth quarter of 2026; a potential MHRA early market access decision is expected in early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611100815NEWSFILECNPR____20261110_323275_1) on November 10, 2026, and is solely responsible for the information contained therein.